Semax and Selank are synthetic heptapeptides which have been studied in experimental neuroscience and molecular research; even though both of them have a C-terminal Pro-Gly-Pro (PGP) sequence they differ in the other amino acids, in their molecular origins and in the experimental pathways that have been examined in the published studies.
Research on Semax has involved the measurement of neurotrophin signalling and gene expression, and studies on Selank have looked at GABA-associated neurotransmission and other molecular endpoints. The two peptides have also been tested in some of the same laboratory systems, enabling a comparison of their experimental properties under defined conditions.
Semax vs Selank: A Research Comparison
| Research Feature | Semax | Selank |
|---|---|---|
| Amino-Acid sequence | Met-Glu-His-Phe-Pro-Gly-Pro | Thr-Lys-Pro-Arg-Pro-Gly-Pro |
| Structural background | ACTH(4-7) sequence plus PGP | Tuftsin-related sequence plus PGP |
| Peptide Length | 7 amino acids | 7 amino acids |
| Investigated Areas | Neurotrophin signalling, gene expression, experimental cerebral ischaemia | GABA-associated signalling, gene expression, peptide degradation |
| Shared experimental area | Enkephalin-degrading enzymes | Enkephalin-degrading enzymes |
These categories describe areas of experimental investigation rather than established physiological or clinical outcomes.
How Do Semax and Selank Differ Structurally?
Semax and Selank are both seven-amino-acid peptides, but their sequences are not identical.
Semax has the sequence:
Met-Glu-His-Phe-Pro-Gly-Pro
Its N-terminal region is derived from the ACTH(4–7) sequence, while its final three residues form the PGP sequence.
Selank has the sequence:
Thr-Lys-Pro-Arg-Pro-Gly-Pro
Its first four residues correspond to a tuftsin-related sequence, followed by the same PGP sequence found at the C-terminus of Semax.
The shared PGP region provides one basis for comparative peptide research, but sequence similarity alone does not establish equivalent molecular interactions or experimental responses.
What Has Semax Research Examined?
Semax has been investigated using molecular and gene-expression measurements, including research involving the brain-derived neurotrophic factor (BDNF) signaling system.
BDNF and TrkB Signalling
BDNF is a signalling protein involved in neuronal biology, while tropomyosin receptor kinase B (TrkB) is one of its receptors.
In a rat study, researchers measured BDNF protein, BDNF mRNA, TrkB mRNA and TrkB phosphorylation in hippocampal tissue following experimental Semax exposure. Differences were reported in several of these molecular measurements.
Other experimental work has examined the transcription of Bdnf, Ngf and their receptor-associated genes across different brain regions and sampling periods.
These findings concern specific molecular endpoints under defined experimental conditions. Changes in neurotrophin-associated gene expression do not independently establish broader functional or therapeutic outcomes.
Broader Gene-Expression Research
Semax has also been examined using transcriptomic methods that allow researchers to measure changes across larger groups of genes.
Such studies can identify signalling pathways or molecular processes for further investigation. However, differential gene expression does not necessarily identify a direct molecular target, and findings should remain specific to the experimental model in which they were observed.
What Has Selank Research Examined?
Selank research has included investigations of gene expression associated with GABAergic neurotransmission.
GABA, or gamma-aminobutyric acid, is an inhibitory neurotransmitter involved in multiple neuronal signalling pathways. Rather than establishing that Selank acts through a single GABA-related mechanism, researchers have examined individual molecular components of these pathways.
One study investigated gene-expression patterns in rat frontal cortex following experimental exposure to Selank or GABA. Researchers reported differences involving genes associated with GABA receptors, transporters, ion channels and other components of neurotransmission.
The observed patterns also varied according to the measurement period.
These findings provide a basis for investigating possible relationships between Selank and GABA-associated signalling, but they do not establish GABA as a single mechanism responsible for every experimental observation involving Selank.
Where Does Semax and Selank Research Overlap?
Despite their different structural origins, Semax and Selank have occasionally been examined within the same experimental system.
One example concerns enkephalin-degrading enzymes.
Enkephalins are endogenous peptides that undergo enzymatic degradation. In one laboratory study, researchers investigated Semax and Selank using enkephalin-degrading enzymes in human serum in vitro.
Both peptides were associated with concentration-dependent differences in the enzyme activity measured under the assay conditions, with different IC50 values reported.
This provides a useful direct comparison because both compounds were evaluated using the same experimental framework.
However, an in vitro enzyme assay measures molecular interactions under controlled laboratory conditions. Results from this type of experiment should not automatically be extrapolated to intact biological systems.
Why Should Semax and Selank Be Compared by Experimental Endpoint?
Semax and Selank are sometimes broadly associated with different functional outcomes. This approach can obscure what individual experiments have actually measured.
A more precise comparison considers:
- the peptide sequence being investigated;
- the experimental model;
- the tissue or biological material examined;
- the molecular pathway under investigation; and
- the specific analytical endpoint measured.
For example, measuring BDNF transcription is different from measuring GABA-associated gene expression, and neither measurement independently demonstrates a broader functional outcome.
Similarly, results from an isolated enzyme assay should not be treated as equivalent to results obtained from tissue or animal models.
What Are the Limitations of Semax vs Selank Research?
Several factors limit direct comparisons between Semax and Selank.
First, much of the mechanistic literature involves animal models, isolated biological materials or laboratory assays. Results should therefore remain connected to the model in which they were obtained.
Second, the studies use different experimental designs. Variables can include tissue type, brain region, analytical technique, sampling interval and the molecular endpoint being measured.
Third, molecular changes do not necessarily establish direct molecular targets. A difference in gene transcription, for example, may identify a pathway for further investigation without demonstrating that the peptide directly interacts with the encoded protein.
Finally, the shared PGP sequence does not establish equivalent molecular behaviour. Each peptide should be investigated as a separate compound.
What Does the Semax vs Selank Research Show?
Semax and Selank are structurally distinct synthetic heptapeptides with partially overlapping but different research histories.
Semax contains an ACTH-derived sequence combined with PGP and has been examined in studies involving neurotrophin signalling and gene-expression measurements.
Selank contains a tuftsin-related sequence combined with PGP and has been investigated using GABA-associated gene-expression and neurotransmission-related endpoints.
Both peptides have also been examined within the same laboratory systems, including research involving enkephalin-degrading enzymes.
Current evidence therefore supports treating Semax and Selank as separate experimental compounds whose findings should be interpreted according to the specific model, pathway and analytical endpoint being studied.
Semax vs Selank Research FAQs
No. Semax and Selank are separate seven-amino-acid peptides with different sequences, although both contain a C-terminal Pro-Gly-Pro sequence.
Semax has the sequence Met-Glu-His-Phe-Pro-Gly-Pro and contains an ACTH(4–7)-derived region followed by PGP.
Selank has the sequence Thr-Lys-Pro-Arg-Pro-Gly-Pro, consisting of a tuftsin-related sequence followed by PGP.
Yes. Experimental studies have measured BDNF expression, BDNF protein and TrkB-associated signalling following Semax exposure in animal models.
Yes. Researchers have examined gene-expression changes associated with GABAergic neurotransmission following experimental Selank exposure.
Yes. One in vitro study examined both peptides in relation to enkephalin-degrading enzymes in human serum, allowing their activity to be compared within the same laboratory assay.
Scientific references
- 1 Dolotov OV, Karpenko EA, Inozemtseva LS, Seredenina TS, Levitskaya NG, Rozyczka J, Dubynina EV, Novosadova EV, Andreeva LA, Alfeeva LY, Kamensky AA, Grivennikov IA, Myasoedov NF, Engele J. Semax, an analog of ACTH(4-10) with cognitive effects, regulates BDNF and trkB expression in the rat hippocampus. Brain Res. 2006 Oct 30;1117(1):54-60. doi: 10.1016/j.brainres.2006.07.108. https://pubmed.ncbi.nlm.nih.gov/16996037/
- 2 Dmitrieva VG, Povarova OV, Skvortsova VI, Limborska SA, Myasoedov NF, Dergunova LV. Semax and Pro-Gly-Pro activate the transcription of neurotrophins and their receptor genes after cerebral ischemia. Cell Mol Neurobiol. 2010 Jan;30(1):71-9. doi: 10.1007/s10571-009-9432-0. https://pubmed.ncbi.nlm.nih.gov/19633950/
- 3 Volkova A, Shadrina M, Kolomin T, Andreeva L, Limborska S, Myasoedov N, Slominsky P. Selank Administration Affects the Expression of Some Genes Involved in GABAergic Neurotransmission. Front Pharmacol. 2016 Feb 18;7:31. doi: 10.3389/fphar.2016.00031. https://pubmed.ncbi.nlm.nih.gov/26924987/
- 4 Kost NV, Sokolov OIu, Gabaeva MV, Grivennikov IA, Andreeva LA, Miasoedov NF, Zozulia AA. Ingibiruiushchee deĭstvie semaksa i selanka na énkefalindegradiruiushchie fermenty syvorotki krovi cheloveka [Semax and selank inhibit the enkephalin-degrading enzymes from human serum]]. Bioorg Khim. 2001 May-Jun;27(3):180-3. Russian. doi: 10.1023/a:1011373002885. PMID: 11443939. https://pubmed.ncbi.nlm.nih.gov/11443939/
Research-use disclaimer: For research and laboratory use only. Not for human or animal consumption.
